Perceived Quality of Treatment Decisions and Determinants of Decisional Conflict in Early-Stage Relapsing–Remitting Multiple Sclerosis

INTRODUCTION: Selecting a disease-modifying therapy (DMT) for relapsing-remitting multiple sclerosis (RRMS) is a preference-sensitive decision where shared decision-making (SDM) is essential. This study aimed to evaluate the perceived quality of the SDM process and identify independent determinants of decisional conflict among patients with early-stage RRMS. METHODS: This non-interventional, cross-sectional, multicenter study across 16 Spanish neuroimmunology clinics evaluated adults with early RRMS (≤ 3 years disease duration from diagnosis) receiving DMTs. SDM process quality and decisional conflict were assessed using the AGA-25 questionnaire and the SURE tests, respectively. Multivariable logistic regression models were constructed to identify independent determinants of high process satisfaction and decisional conflict. RESULTS: The evaluable population comprised 145 patients (mean age 37.6 years, 69.0% female). Participants evaluated the SDM process favorably (mean total AGA-25 score 67.1 [SD 9.1]). High process satisfaction was reported by 26.2% of patients (n = 38). In multivariable analysis, male sex and a higher total number of relapses since disease onset were associated with significantly lower odds of high process satisfaction, whereas higher decisional certainty was an independent positive determinant. Clinically significant decisional conflict was present in 27.1% of participants (n = 36). In the multivariable model, greater illness-related uncertainty, a more threatening illness perception, and higher fatigue impact independently increased the likelihood of decisional conflict. CONCLUSION: Although patients with early-stage RRMS generally report a favorable overall perception of collaborative treatment selection, high process satisfaction is attained by only approximately one-quarter of patients. Furthermore, clinically significant decisional conflict affects over 27% of individuals early in their disease course. This decisional distress is driven predominantly by the subjective emotional and perceptual burden of living with MS, rather than objective physical disability.

Authors

Institutions

Publication Details

Journal
Neurology and Therapy
Published
2026-11-12
DOI
https://doi.org/10.1007/s40120-026-01078-9
Primary Topic
Multiple Sclerosis Research Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Perceived Quality of Treatment Decisions and Determinants of Decisional Conflict in Early-Stage Relapsing–Remitting Multiple Sclerosis

Jesús Martín-Martínez, Olga Carmona, José Luis Sánchez-Menoyo, Inés González‐Suarez et al.
Neurology and Therapy
Multiple Sclerosis Research Studies
article

Perceived Quality of Treatment Decisions and Determinants of Decisional Conflict in Early-Stage Relapsing–Remitting Multiple Sclerosis

Jesús Martín-Martínez, Olga Carmona, José Luis Sánchez-Menoyo, Inés González‐Suarez, Antonio Candeliere-Merlicco, Ignacio Casanova, Montserrat Gómez-Gutiérrez, Jorge Mauriño, Elena García-Arcelay, Elena Álvarez, Miguel Ángel Hernández, Laura Borrega, Pablo López-Muñoz, Eva María Pacheco, Carmen Calles, Ángel Pérez-Sempere, Ana Belén Caminero, Aida Orviz, Jacobo Caruncho, Raquel Piñar
article en

Abstract

INTRODUCTION: Selecting a disease-modifying therapy (DMT) for relapsing-remitting multiple sclerosis (RRMS) is a preference-sensitive decision where shared decision-making (SDM) is essential. This study aimed to evaluate the perceived quality of the SDM process and identify independent determinants of decisional conflict among patients with early-stage RRMS. METHODS: This non-interventional, cross-sectional, multicenter study across 16 Spanish neuroimmunology clinics evaluated adults with early RRMS (≤ 3 years disease duration from diagnosis) receiving DMTs. SDM process quality and decisional conflict were assessed using the AGA-25 questionnaire and the SURE tests, respectively. Multivariable logistic regression models were constructed to identify independent determinants of high process satisfaction and decisional conflict. RESULTS: The evaluable population comprised 145 patients (mean age 37.6 years, 69.0% female). Participants evaluated the SDM process favorably (mean total AGA-25 score 67.1 [SD 9.1]). High process satisfaction was reported by 26.2% of patients (n = 38). In multivariable analysis, male sex and a higher total number of relapses since disease onset were associated with significantly lower odds of high process satisfaction, whereas higher decisional certainty was an independent positive determinant. Clinically significant decisional conflict was present in 27.1% of participants (n = 36). In the multivariable model, greater illness-related uncertainty, a more threatening illness perception, and higher fatigue impact independently increased the likelihood of decisional conflict. CONCLUSION: Although patients with early-stage RRMS generally report a favorable overall perception of collaborative treatment selection, high process satisfaction is attained by only approximately one-quarter of patients. Furthermore, clinically significant decisional conflict affects over 27% of individuals early in their disease course. This decisional distress is driven predominantly by the subjective emotional and perceptual burden of living with MS, rather than objective physical disability.

Neurology and Therapy
Hospital Universitario Nuestra Señora de Candelaria (ES), Hospital Universitario de Torrejón (ES), Hospital Universitario Fundación Alcorcón (ES), Hospital Rafael Méndez (ES), Hospital San Pedro de Alcántara (ES), Hospital Universitario Miguel Servet (ES), Hospital de Galdakao (ES), Hospital Juan Ramón Jiménez (ES), Hospital Universitario Fundación Jiménez Díaz (ES), Hospital General Universitario de Alicante Doctor Balmis (ES), Roche (Spain) (ES), Hospital Universitario Son Espases (ES), Fundació Salut Empordà (ES)
Roche España
Good health and well-being
Multiple Sclerosis Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon